DMD and Duchenne muscular dystrophy: In DMD, microdystrophin expression is presumed to be a surrogate biomarker of clinical benefit based on extensive preclinical data in combination with known mechanisms of action and outcomes in participants with mutations that result in shortened dystrophin proteins [45, 46, 80].